Home/Pipeline/Personalized Medicine Assays (Patient-Derived Explants)

Personalized Medicine Assays (Patient-Derived Explants)

Oncology

Research-Use OnlyActive

Key Facts

Indication

Oncology

Phase

Research-Use Only

Status

Active

Company

Aurita Bioscience

About Aurita Bioscience

Aurita Bioscience is a private biotechnology company developing a disruptive 3D cell culture ecosystem designed to overcome the limitations of traditional 2D and hydrogel-based 3D models. Its core technologies—LLS® microgels and Darcy™ perfusion plates—create a tunable, physiologically relevant microenvironment that supports complex cellular interactions, prolonged viability, and high-fidelity in situ imaging. The company is actively engaged in collaborative research projects in oncology, infectious disease (including SARS-CoV-2), and immunotherapy (CAR-T), positioning itself as a critical enabler for more predictive drug discovery and development.

View full company profile

Therapeutic Areas

Oncology Infectious Disease Immunology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active